Kinesin Eg5 Targeting Inhibitors as a New Strategy for Gastric Adenocarcinoma Treatment.
Antineoplastic Agents
/ pharmacology
Caspase 3
/ metabolism
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Survival
/ drug effects
Humans
Kinesins
/ antagonists & inhibitors
Matrix Metalloproteinase 9
/ metabolism
Models, Molecular
Stomach Neoplasms
/ drug therapy
Thiadiazoles
/ chemistry
Tubulin
/ metabolism
bcl-2-Associated X Protein
/ metabolism
AGS
Eg5
K858
kinesin
monoastral spindle
thiadiazoline
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
31 Oct 2019
31 Oct 2019
Historique:
received:
09
10
2019
revised:
26
10
2019
accepted:
30
10
2019
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
9
4
2020
Statut:
epublish
Résumé
The Kinesins are proteins involved in several biological processes such as mitosis, intracellular transport, and microtubule movement. The mitotic process is allowed by the correct formation of the mitotic spindle which consists of microtubules originating from the spindle poles. In recent years, kinesin Eg5 inhibitors were studied as new chemotherapeutic drugs, due to the lack of side effects and resistance mechanisms. The aim of this work was to investigate the molecular signaling underlying the administration of novel kinesis Eg5 inhibitors in an in vitro model of gastric adenocarcinoma. Data obtained from analogues of
Identifiants
pubmed: 31683688
pii: molecules24213948
doi: 10.3390/molecules24213948
pmc: PMC6864856
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
KIF11 protein, human
0
Thiadiazoles
0
Tubulin
0
bcl-2-Associated X Protein
0
Caspase 3
EC 3.4.22.-
Matrix Metalloproteinase 9
EC 3.4.24.35
Kinesins
EC 3.6.4.4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
World J Gastroenterol. 2015 Nov 21;21(43):12261-73
pubmed: 26604635
Science. 1999 Oct 29;286(5441):971-4
pubmed: 10542155
Mol Cell Biol. 2007 Jan;27(2):689-98
pubmed: 17101792
Tumour Biol. 2016 Mar;37(3):3505-14
pubmed: 26453114
Gastroenterol Clin North Am. 2013 Jun;42(2):211-7
pubmed: 23639637
Semin Oncol. 1992 Dec;19(6):646-62
pubmed: 1361079
Eur J Med Chem. 2015 Nov 13;105:245-62
pubmed: 26498571
Biochim Biophys Acta. 2014 Mar;1843(3):603-17
pubmed: 24333402
Anticancer Drugs. 2018 Aug;29(7):674-681
pubmed: 29738338
J Pathol. 2010 Jun;221(2):221-8
pubmed: 20455257
Molecules. 2019 May 25;24(10):null
pubmed: 31130597
Per Med. 2018 Mar;15(2):79-86
pubmed: 29714127
Nat Rev Mol Cell Biol. 2009 Oct;10(10):682-96
pubmed: 19773780
Eur J Med Chem. 2018 Aug 5;156:641-651
pubmed: 30031975
BMC Cancer. 2010 Jun 09;10:270
pubmed: 20534121
Invest New Drugs. 2018 Feb;36(1):28-35
pubmed: 28965307
Oncotarget. 2017 Jul 10;8(37):62208-62216
pubmed: 28977938
Nat Rev Cancer. 2012 Jul 24;12(8):527-39
pubmed: 22825217
Cancer Res. 2009 May 1;69(9):3901-9
pubmed: 19351824
Cancer Metastasis Rev. 2009 Jun;28(1-2):197-208
pubmed: 19156502
Clin Cancer Res. 2012 Apr 15;18(8):2220-9
pubmed: 22351692
Arch Biochem Biophys. 2008 Jan 15;469(2):220-31
pubmed: 17999913
Invest New Drugs. 2016 Aug;34(4):399-406
pubmed: 26994617
Pathobiology. 2017;84(1):16-24
pubmed: 27459100
Cancer Sci. 2013 Jun;104(6):651-6
pubmed: 23438337
Cancers (Basel). 2019 Jun 17;11(6):null
pubmed: 31213005
Nat Rev Dis Primers. 2017 Jun 01;3:17036
pubmed: 28569272
PLoS One. 2015 Jun 02;10(6):e0129255
pubmed: 26035434